Cas:887591-37-9 3-(4-morpholin-4-ylphenyl)-1,2-oxazol-5-amine manufacturer & supplier

Chemical Name:3-(4-morpholin-4-ylphenyl)-1,2-oxazol-5-amine

CAS.NO:887591-37-9

Synonyms:3-(4-morpholin-4-ylphenyl)-1,2-oxazol-5-amine

Molecular Formula:C₁₃H₁₅N₃O₂

Molecular Weight:245.27700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:64.52000

Exact Mass:245.11600

LogP:2.40660

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-(4-morpholin-4-ylphenyl)-1,2-oxazol-5-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(4-morpholin-4-ylphenyl)-1,2-oxazol-5-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(4-morpholin-4-ylphenyl)-1,2-oxazol-5-amine Use and application,3-(4-morpholin-4-ylphenyl)-1,2-oxazol-5-amine technical grade,usp/ep/jp grade.

Related News: With the advancement of supply-side structural reforms, the production of bulk APIs in China will become more concentrated, and the technology will be further improved. 3-(4-morpholin-4-ylphenyl)-1,2-oxazol-5-amine manufacturer China has asked the European Union for help in buying urgently needed medical supplies from its member countries, the China��s official Xinhua news agency said on Saturday. 3-(4-morpholin-4-ylphenyl)-1,2-oxazol-5-amine supplier With the advancement of supply-side structural reforms, the production of bulk APIs in China will become more concentrated, and the technology will be further improved. 3-(4-morpholin-4-ylphenyl)-1,2-oxazol-5-amine vendor In addition, although the API and intermediate industries are capital-intensive and technology-intensive industries, new competitors are still joining. 3-(4-morpholin-4-ylphenyl)-1,2-oxazol-5-amine factory China has granted conditional approval to its first self-developed treatment for Alzheimer��s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.